Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

(2014) Antonio Palumbo et al.   LANCET ONCOLOGY

Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

(2013) M Pozotrigo et al.   BONE MARROW TRANSPLANTATION

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

(2011) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

(2010) C. B. Reeder et al.   BLOOD

High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma

(2010) H W Auner et al.   BONE MARROW TRANSPLANTATION

Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents

(2010) C. Fernandez de Larrea et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

(2009) S. Kumar et al.   BLOOD

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

(2009) H. M. Lokhorst et al.   BLOOD

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

(2009) John F. DiPersio et al.   JOURNAL OF CLINICAL ONCOLOGY

Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis

(2009) Sergio Giralt et al.   JNCI-Journal of the National Cancer Institute

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis

(2009) A. Kumar et al.   JNCI-Journal of the National Cancer Institute

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

(2008) Tomer Mark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

(2008) L. Rosinol et al.   BLOOD

Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma

(2008) P Moreau   BONE MARROW TRANSPLANTATION

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

(2008) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY